Core Viewpoint - Mangoceuticals, Inc. is making significant advancements in its research on respiratory illness prevention technologies, particularly focusing on H1N1 and H5N1 viruses, showcasing the potential of its proprietary formulations [1][2][3][4]. Research Progress - The company has progressed to the next stage of its H1N1 efficacy study, which has shown promising preliminary results, including a significant reduction in viral load [2][3]. - A new cohort for evaluating the technology against the H5N1 virus is being structured to run concurrently with the ongoing H1N1 study [2][4]. Technology and Innovation - The studies utilize Mangoceuticals' proprietary formulation of advanced polyphenol and zinc chemistry, indicating a strong foundation for further exploration and applications [3]. - The company's commitment to addressing global health concerns through innovative solutions is emphasized by its ongoing research efforts [4]. Market Focus - Mangoceuticals is dedicated to developing a variety of men's health and wellness products and services, particularly in the telemedicine sector, which includes areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [5].

Core Insights - Mangoceuticals, Inc. has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc. to market and distribute Dermytol®, a clinically proven skincare treatment aimed at improving skin tone and reducing hyperpigmentation [1][5] Company Overview - Mangoceuticals, Inc. focuses on developing and selling men's wellness products through a secure telemedicine platform, with a growing portfolio that includes various health and wellness solutions [7][8] - Propre Energie, Inc. specializes in plant-based, non-retinol skincare solutions under the Dermytol® brand, emphasizing research and innovation in developing safe and effective products [6] Product Details - Dermytol® is an advanced, plant-based formula designed to address pigmentation issues such as dark spots and uneven skin tone, utilizing a proprietary blend of clinically validated ingredients [2][3] - The formulation includes canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera, providing a safer alternative to traditional skin treatments like hydroquinone [2] Market Insights - The global skincare market is projected to reach approximately $218 billion by 2029, with a compound annual growth rate (CAGR) of 3.61% from 2025 to 2029 [4] - The plant-based skincare segment is expected to grow from $789.75 million in 2023 to $1.62 billion by 2033, reflecting a robust CAGR of 7.5% over the next decade, driven by consumer demand for natural and effective skincare solutions [4] Strategic Partnership - The partnership allows Mangoceuticals to leverage its marketing and distribution infrastructure to accelerate Dermytol®'s penetration in North and South American markets, with the product available in both patch and cream formulations [5]

Core Insights - Mangoceuticals, Inc. has acquired a patent for mushroom-derived compositions aimed at enhancing men's health and wellness through innovative solutions [1][2][3] - The global functional mushroom market is projected to grow from USD 32.41 billion in 2024 to USD 48.59 billion by 2029, with a CAGR of 8.44% [3] Company Developments - The acquired patent includes nutraceutical compositions from functional mushrooms like Cordyceps sinensis, Ganoderma lucidum (Reishi), and Hericium erinaceus (Lion’s Mane), which offer various health benefits [2][4] - The company plans to develop a new line of wellness products, including dietary supplements and functional foods, leveraging the unique properties of these mushroom-derived formulations [4] Market Context - The acquisition aligns with the growing consumer awareness of natural health solutions, positioning the company to capitalize on the expanding nutraceutical market [3] - Functional mushrooms are becoming increasingly important in the nutraceutical sector due to their scientifically validated benefits and versatility [3]

Company Overview - Mangoceuticals, Inc. focuses on developing, marketing, and selling men's health and wellness products through a secure telemedicine platform [5] - The company has identified men's wellness telemedicine services, particularly in erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management, as a growing sector [5] - Consumers can utilize MangoRx's telemedicine platform for prescription requests, which are reviewed by a physician and fulfilled through a partner compounding pharmacy [5] Event Participation - Mangoceuticals, Inc. will present at the Centurion One Capital 2nd Annual Bahamas Summit on October 23, 2024, at 11:10 EDT [1] - The summit will feature presentations from various public and private companies to prominent investors from Canada, the United States, and abroad [2] - The event will include presentations, Q&A sessions, panel discussions, and one-on-one investor meetings [3] Event Details - The Centurion One Capital 2nd Annual Bahamas Summit will take place on October 22-23, 2024, at the Rosewood Baha Mar Hotel [3] - The summit will run from 9:00 AM EDT to 4:00 PM EDT each day [3] - Centurion One Capital is an independent investment banking firm dedicated to supporting the growth of companies in North America [3]

Financial Results - Mangoceuticals, Inc. reported financial results for the three and six months ended June 30, 2024[3]. - The press release regarding financial results was issued on August 15, 2024[3]. - The financial results are not deemed "filed" under the Securities Exchange Act of 1934[3]. Company Classification - The company is classified as an emerging growth company under the Securities Act[2]. - The trading symbol for the common stock is MGRX, listed on the Nasdaq Capital Market[2]. Forward-Looking Statements - The report includes forward-looking statements that may involve risks and uncertainties affecting future performance[5]. - The company has no obligation to update or revise forward-looking statements after the date they are made[5]. - The report includes cautionary statements regarding potential factors affecting financial results[5]. Company Information - The company’s principal executive office is located in Dallas, Texas[1]. - The company’s IRS Employer Identification Number is 87-3841292[1].

Core Viewpoint - Mangoceuticals, Inc. has appointed Dr. Douglas Christianson as the Director of the Medical Research and Product Innovation Department, aiming to enhance its portfolio of men's health and wellness products [1][2]. Company Overview - Mangoceuticals, Inc. focuses on developing, marketing, and selling men's health and wellness products, particularly in erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies [1][3]. - The company operates through a secure telemedicine platform, allowing consumers to request prescriptions that are reviewed by physicians and fulfilled by a partner compounding pharmacy [3]. Leadership Appointment - Dr. Douglas Christianson brings extensive experience in male optimization therapies and regenerative medicine, with a background in biomedical sciences and a medical degree from Bastyr University California [2][7]. - His role will include driving new product development initiatives, conducting market research, and developing custom compound formulations for MangoRx's healthcare products [7]. Strategic Focus - The company aims to expand its product offerings and establish new product categories, leveraging Dr. Christianson's expertise to stay ahead of market trends and evolving healthcare needs [2][7]. - Dr. Christianson emphasizes a patient-centered approach, focusing on empowering individuals to make informed lifestyle choices for long-term wellness [2][8].

About MangoRx Cautionary Note Regarding Forward-Looking Statements expectations or beliefs concerning future events and can generally be identified using statements that include words such as "estimate," "expects," "project," "believe," "anticipate," "intend," "plan," "foresee," "forecast," "likely," "will," "target" or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control which could cause actual ...

Jacob Cohen, CEO and Co-Founder of MangoRx, commented, "We are thrilled to partner with the International Society of Frontier Life Sciences and Technology to expand our presence in China and the Asia Pacific region. This agreement aligns with our strategic goal of reaching new international markets and providing men worldwide with access to our innovative health solutions. According to the Economic and Social Commission for Asia and the Pacific (ESCAP), there are an estimated 400 million males aged 35 and a ...

DALLAS, TEXAS, July 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce that it has secured a strategic partnership with the International Society of Frontier Life Sciences and Technology (ISFLST) for the distribution of its products in C ...

Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that it has received a Notice of Acceptance for Australian Patent Application No. 2020235666, which is the National Phase of International Application No. PCT/US2020/02 ...